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Abstract
Purpose—The International Lamotrigine Pregnancy Registry monitored for a signal of a 
substantial increase in the frequency of major congenital malformations associated with 
lamotrigine exposures in pregnancy over an 18-year period. Key methodological lessons are 
discussed. Methods The strengths and weaknesses of the Registry were assessed using quantifiable 
methodological and operational parameters including enrollment, completeness of exposure and 
outcome data reporting, and lost to follow-up. The choice of comparator groups and stopping rules 
for registry closure were critically evaluated.
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Results—The reliance on voluntary reporting was associated with a clustered geographical 
distribution of registered pregnancies. The enrollment rate increased over time with new approvals 
and indications for lamotrigine and publication of interim data. Reporter burden was minimized 
through a streamlined data collection approach resulting in a high level of completeness of 
exposure and primary outcome data. Lost to follow-up rates were high (28.5% overall) 
representing a major limitation; incentives to increase the completeness of reporting failed to 
reduce rates. A lack of an internal comparator group complicated data interpretation; but external 
comparisons with multiple external groups allowed an assessment of consistency of outcome data 
across multiple data sources. A lack of a priori closure criteria prolonged the life of the Registry, 
and consideration of regulatory guidelines on this subject is encouraged at the time of conception 
of future registries.
Conclusions—A successful pregnancy exposure registry requires ongoing flexibility and 
continuous re-assessment of enrollment, recruitment, and retention methods and the availability of 
comparison data, throughout its lifecycle.
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INTRODUCTION
Regulatory authorities encourage the establishment of pregnancy registries to monitor 
medication safety in pregnancy when exposure in women of childbearing age is expected to 
be common, yet these studies are not without challenges.1,2 Anti-epileptic drugs (AED) are 
often the subject of such monitoring because of the large number of women of childbearing 
age with epilepsy2–5 and the dangers posed by uncontrolled seizures to the mother and fetus 
if medication is discontinued during pregnancy.6 The emergence of a new generation of 
AEDs in the early 1990s, following an older generation of anticonvulsants with evidence of 
teratogenic potential,5–10 stimulated the establishment of several AED pregnancy registries 
in the early 1990s. The International Lamotrigine Pregnancy Registry, started in 1992 by 
Burroughs Wellcome, was one of the first registries established to monitor the safety in 
pregnancy of one of these new AEDs, LAMICTAL™ (lamotrigine). The primary objective 
was to monitor for signals of a substantial increase in the frequency of major congenital 
malformations (MCMs). This paper reviews key methodological lessons from the Registry 
over its 18 years.
REGISTRY DESIGN
The Registry’s methods are described elsewhere.11–13 Briefly, this international, voluntary 
registry enrolled women who had taken at least one dose of lamotrigine during pregnancy. 
Health care providers (HCPs) enrolled women anonymously and also provided follow-up 
data. Enrollment early in pregnancy was encouraged, but not required, to capture first 
trimester exposures and to avoid enrollment based on knowledge of pregnancy outcome 
from prenatal testing. Exposure and pregnancy details were collected at enrollment. 
Information about pregnancy outcome, particularly the presence of an MCM, was collected 
around the pregnancy due date. An MCM case was defined as any live or stillborn infant, or 
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electively terminated fetus, of any gestational age with a major structural or chromosomal 
abnormality diagnosed before 6 years of age; however, the Registry primarily captured 
major defects that were external, recognizable in the delivery room and/or symptomatic 
shortly after birth. Rather than enrolling a control group, the Registry’s results were 
descriptively compared with data from population-based cohorts14–16 and from cohorts of 
women exposed during pregnancy to AED monotherapy.17–24
Reports of MCMs were reviewed by the pediatrician on the Registry’s Scientific Advisory 
Committee in accordance with the case definition and coding schema used by the 
Metropolitan Atlanta Congenital Defects Program (MACDP), an active population-based 
birth defects surveillance program.25,26 Consistent with the MACDP, minor birth defects 
were not systematically collected.26 The distinction between major and minor 
malformations and its significance is an area of ongoing discussion among experts in the 
fields of dysmorphology and clinical genetics.12 In some registries, the MCM case definition 
includes outcomes with a cluster of two or more minor defects (defects of secondary 
importance), in the absence of a diagnosed MCM, to increase the sensitivity of registry 
monitoring and avoid missing a potential signal.27
Limiting birth defect ascertainment to the period of just after birth is consistent with the 
methods used in other registries initiated in the 1990s.27–29 In newer registries, infants are 
typically followed for up to one year of age,30–35 which may improve the capture of MCMs 
diagnosed later in infancy and result in a higher overall rate of MCMs. Infant follow-up 
requires permission from the parent(s) to contact the pediatric HCP and adds complexity to a 
voluntary registry.
The Registry closed in March 2010 following the enrollment of 3416 pregnancies from 43 
countries. Of those, 2444 had known outcomes and 972 (28.5%) were lost to follow-up 
(LTFU) (Table 1). The prevalence of MCM following first trimester lamotrigine 
monotherapy exposure was 2.2% (95% Confidence Interval (CI): 1.6–3.1%)12,13,36 similar 
to estimates in general population14–16 and AED-specific cohorts.18,23
CHALLENGES TO EXTERNAL VALIDITY
Although this was an international registry, the majority of exposures were reported from a 
few countries: 65% from the USA and 20% from Poland, UK, Germany, Sweden, and 
Denmark. This reporting pattern does not mirror the global pattern of marketing approvals; 
rather, it likely reflects the benefits of a toll-free telephone number for US enrollments, 
whereas non-US enrollments were channeled through the Registry sponsor’s local operating 
companies. A search for pregnancy exposure registries (or cohort or surveillance studies 
focusing on potential teratogenicity of medications) in the databases of Clinicaltrials.gov 
and the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance 
reflected a similar pattern.37,38 Among 81 pregnancy studies in Clinicaltrials.gov, most were 
conducted in the USA (n = 51), followed by Europe (n = 18), and other regions with one to 
three studies each.37 The European Network of Centres for Pharmacoepidemiology and 
Pharmacovigilance search revealed only four studies (one in the UK and three multi-
national).38 It might be surmised that companies required by the Food and Drug 
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Administration to conduct a pregnancy registry could limit their target population to the 
USA to minimize financial resources and avoid the somewhat complex and labor-intensive 
processes required to comply with national data privacy regulations in multiple countries, 
particularly for rare exposures. Within Europe, it is increasingly possible to harness the 
existing surveillance infrastructure as many countries now have birth defect surveillance 
programs, capturing medication exposure, with data provided centrally to EUROCAT39 for 
aggregation and evaluation of safety signals.
DIFFICULTIES IN PROJECTING ENROLLMENT
Because of uncertainties around a new medication’s uptake, and future indications, it is 
challenging to define enrollment targets, estimate the time needed to reach enrollment 
targets, and develop optimal enrollment methods when initiating a pregnancy registry. 
Enrollment in this Registry was open to all eligible women whose HCPs were willing to 
participate. Because of the rarity of exposed pregnancies in the patient population, this study 
was not site-based with pre-selected investigators. HCPs were informed of the Registry 
through awareness communications, such as providing a toll-free registry telephone number 
published in the prescribing information, sending a copy of the bi-annual registry interim 
report to all HCPs who had enrolled a subject, and including registry information on the 
FDA listing of pregnancy registries.
During the first years of the Registry, enrollment was low (averaging 40 prospective 
exposures per year globally) (Figure 1) likely reflecting the initial narrow indication for 
lamotrigine as adjunctive therapy in adults with partial seizures. Prospective enrollments 
were defined as pregnant exposed women registered before the outcome of pregnancy was 
known. To maintain prospective enrollment and avoid bias toward reporting of pregnancies 
known to have defects, the Registry excluded pregnancies with prenatal diagnosis of a 
defect at the time of enrollment from the primary analyses. Such pregnancies were classified 
as retrospective and analyzed separately. By enrolling as prospective women who have had 
some form of prenatal testing (e.g., ultrasound) that was considered normal, there may be a 
bias toward normal pregnancy outcomes. Having had a prenatal test that is normal does 
provide information about the infant’s status and lessens the likelihood that a major 
abnormality will be identified later or after delivery. A truly prospective enrollment would 
be a pregnancy for which no testing had been done (normal or abnormal); however, given 
the high prevalence of prenatal testing, this can be difficult and emphasizes the importance 
of enrollment early in pregnancy.
Enrollment increased at the end of the 1990s following new approvals for lamotrigine, 
including use as monotherapy for seizure treatment and for bipolar disorder. These 
approvals also highlighted the need for modified communication strategies to increase 
awareness of the Registry among different physician groups, for example, among 
psychiatrists following the approval for bipolar disorder. Increased enrollment also 
coincided with the first of regular publications of interim results in peer reviewed journals. 
Awareness efforts were aimed at prescribers,11,13 and most of the reporting came from 
neurologists and to a lesser extent, psychiatrists and obstetric HCPs. Other registries have 
reported enrollment difficulties of a much greater magnitude30,31 despite active awareness 
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strategies that include multiple HCP types and venues. Although awareness is critical to 
enrollment, other factors should be considered including the availability of the target 
population (e.g., prevalence of the indication among women of childbearing age), the 
effectiveness of pregnancy avoidance warnings, and varying degrees of risk/benefit for 
taking a medication during pregnancy in different populations.
The existence of other AED pregnancy registries may have impacted enrollment: several 
national and international pregnancy registries ran concurrently, monitoring AED safety in 
pregnancy. These registries included the North American Anti-Epileptic Drug (NAAED) 
Pregnancy Registry18 and the International Registry for Anti-Epileptic Drugs in Pregnancy 
(EURAP).40 Based on recent reports, the EURAP has enrolled 2568 subjects exposed to 
lamotrigine monotherapy withing 16 weeks of gestation,41 and the NAAED has enrolled 
1562 first trimester lamotrigine monotherapy exposures. 42
Whether there is overlap among women enrolled in these registries remains unclear. 
Information on concurrent enrollment was sought at the time of enrollment into the Registry; 
however, these data are difficult to interpret as different registries relied upon different 
enrollment methods. Hence, an HCP enrolling a patient into the International Lamotrigine 
Pregnancy Registry may have been unaware that this patient had enrolled herself 
independently into the NAAED. The various AED registries function independently; 
therefore, improved communication among them may be useful. However, the identification 
of double enrollments is complicated by the need to maintain patient anonymity in registries 
that do not collect identifying information.
VOLUNTARY REPORTING AND DATA QUALITY
The reliance on voluntary enrollment through HCPs prompted the Registry to collect a core, 
minimal dataset to simplify participation and promote complete reporting, which primarily 
included data required for assessing the exposure-outcome relationship and the potential for 
bias. To minimize reporter burden, the Registry contacted the HCP twice: at enrollment and 
after the estimated date of delivery to assess outcome. At registration, a two-page form was 
used to collect information on maternal demographics, pregnancy and prenatal testing, and 
lamotrigine exposure. At followup, after the expected delivery date, a three-page form was 
used to collect confirmation of exposure and pregnancy outcome information. For 
pregnancies with MCMs, an additional follow-up contact was available, if needed, to 
ascertain details of the MCM and presence of risk factors.
Among the 70 outcomes with reported MCMs, additional details were sought for 31 
(44.3%). Of these, HCPs for 29 (93.5%) cases provided additional information; however, it 
was not always meaningful: several indicated that they had lost contact with the patient (8%) 
or did not have the requested details (7%). At times, the information received did not 
address the request because the reporter was not the associated obstetrician or pediatrician. 
This may represent the challenge of a de-centralized health care system. However, contact 
with multiple HCPs for each mother–infant pair allows for a more comprehensive approach.
Among all prospectively reported pregnancies with known outcomes, data completeness was 
high among critical variables for the exposure type (polytherapy or monotherapy), earliest 
Sinclair et al. Page 5













trimester of exposure, lamotrigine dose, maternal age, and gestational age at delivery (Table 
1). Data were less complete for maternal race, prenatal testing information, and neonatal 
anthropometric measurements at follow-up, and these data were not included in the primary 
analysis. Consequently, data collection could have been further streamlined.
LOSS TO FOLLOW-UP
Losses to follow-up in a pregnancy registry can introduce bias if lost cases are more or less 
likely to have MCMs compared with those completing follow-up. Participants in the 
International Lamotrigine Pregnancy Registry were classified as LTFU if information on 
pregnancy outcome was not obtained after multiple contacts. Among enrolled pregnancies, 
28.5% (972/3416) were LTFU, varying little between the USA and other countries (data 
available upon request). Most LTFU cases (79%) were attributable to practices of the 
participating HCPs: the registering HCP failed to respond to requests for follow-up 
information (64%), the registering HCP left the practice without providing a forwarding 
address (8%), and patient could not be identified by the registering HCP (7%). These reflect 
the limitations of voluntary reporting. Failure of the HCP to identify patients may be related 
to the administrative complexity of tracking patients anonymously through Registry 
identification numbers. An additional 19% of LTFU was due to patients no longer being 
under the care of the registering HCP.
Accepting enrollment directly from women and asking HCPs to obtain informed consent 
from women so that they can be followed up directly can reduce LTFU.43 The Ribavirin 
Pregnancy Registry reported lower LTFU among enrollments initiated by patients (8.3%) 
compared with HCPs (24.7%).30 Loss to follow-up in the NAAED Pregnancy Registry, 
which relies solely on direct enrollment by participating women, is approximately 7% 
among first trimester monotherapy-exposed subjects.20 However, it should be noted that this 
figure does not reflect the potential loss of data from women who refuse to authorize release 
of medical information for confirmation of selected variables. Up to 30% of women have 
been reported to refuse authorization within the NAAED Pregnancy Registry, emphasizing 
the potential for medical record release to impact data accuracy and possibly introduce 
misclassification.42
In 2004, to decrease LTFU, the Registry introduced a stipend to compensate HCPs for time 
spent reporting (up to $150 for each completed patient). An analysis examining LTFU for 
the periods pre-stipend (registry initiation until 1 June 2004) and post-stipend (1 June 2004 
until 2 February 2007) showed little impact of the stipend on LTFU: pre-stipend 24.3% 
(140/576) versus post-stipend 26.8% (184/686). For both periods, the principal reason for 
LTFU was failure of the HCP to respond at follow-up.44 Although it is possible that the 
stipend could have prevented future increases in LTFU, an examination of the LTFU data in 
yearly increments showed no substantial changes in the rate or reasons for LTFU. Because 
of the potential for bias in pregnancy registries, exploring underlying reasons for LTFU and 
implementing strategies for reducing LTFU should be an ongoing activity in any registry.
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INTERNAL OR EXTERNAL COMPARATOR GROUPS?
The choice of comparison data, whether from an internal or external source, is complex. 
Pregnancy registries enrolling exposures to multiple AEDs have used internal comparator 
groups including women with epilepsy unexposed to AEDs or exposed to different 
AEDs.17,23,40 While this approach can minimize bias related to differences in enrollment 
and outcome ascertainment, it does not eliminate confounding by indication. The latter can 
occur when the differences in MCM risk observed between Registry and comparator groups 
are related to disease severity or risk associated with other AEDs. Direct statistically based 
comparisons with groups external to the registry are not without problems and can be 
influenced by methodological differences including patient selection methods, for example, 
hospital-based or population-based ascertainment,14–16 ascertainment of infant health, MCM 
case definition, and duration of infant follow-up after birth.
It may, therefore, be useful to compare registry results with those from multiple studies 
using different methods. Because of a paucity of existing data on AEDs and MCMs at the 
time of inception of the International Lamotrigine Pregnancy Registry, the Registry protocol 
specified a priori use of the MACDP14,15,26 case definition and background data, which had 
been used by others to place accumulating pregnancy registry data into perspective.27,30–32 
Later, as more data were published internationally, the Scientific Advisory Committee 
considered the MCM frequency reported from other cohort studies and AED pregnancy 
registries, as well as population-based reference data, when reviewing Registry results. The 
use of multiple reference data sources was particularly important after the approval of 
lamotrigine for non-epilepsy conditions. This thorough review of cumulative MCM risk was 
considered sufficient to detect a signal for a substantial increase in the risk of MCMs 
associated with lamotrigine. Statistical comparisons across studies were avoided because of 
methodological differences across studies.
Nevertheless, assuming minimal overlapping enrollment across AED registries, descriptive 
comparisons of reported MCM frequencies across multiple sources may provide a means of 
assessing the robustness of the Registry data and placing further context around emerging 
Registry results.
DECISIONS SURROUNDING CLOSURE OF REGISTRY
Regulatory guidelines1 advise pregnancy registry discontinuation if (i) sufficient data 
accumulate to meet the scientific objectives, (ii) poor recruitment or high LTFU result in 
insufficient data to meet objectives, or (iii) alternative methods of data collection become 
possible or preferable. Discontinuation criteria should be defined a priori in the study 
protocol. Registry closure criteria were not pre-specified for this Registry. Contemporary 
registries typically set a goal of enrolling a specific sample size, often between 300 to 500 
pregnancies, based on 80% power calculations aimed to detect a twofold to threefold 
increase in all MCMs relative to a comparator risk.30,31,34 This is sufficient for the objective 
of detecting a substantial increase in the frequency of MCMs.
The lack of a priori closure criteria may have contributed to the Registry’s 18-year duration. 
However, with the enrollment of over 1000 first trimester lamotrigine monotherapy 
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exposures and increasingly narrow confidence intervals, the Scientific Advisory Committee 
considered the Registry had met its primary objective to detect a substantial increase in the 
frequency of all MCMs. Further confidence resulted from the stability of the MCM 
frequency estimate during the second half of the Registry’s lifespan (Figure 2), the precision 
of the estimate, and the 95% confidence interval (1.6–3.1%), at closure.
Over time, the sample size became large enough to observe small numbers of specific 
malformations potentially signaling an elevated risk, but the lack of precision complicated 
interpretation. Because a teratogen is likely to increase the frequency of specific or specific 
combinations of MCMs rather than all MCM types together, it is important to continue to 
use other methods to monitor for potential risks that a pregnancy registry could not detect. 
The Scientific Advisory Committee therefore recommended continued monitoring through 
case control surveillance within the EUROCAT network where cases and controls can be 
identified, and lamotrigine pregnancy exposure can be ascertained.
Whether the Registry could have ended earlier may be debatable. One could argue that if the 
Registry’s aim is to detect a signal for major teratogenicity, this was achieved well before 
the Registry closed. Table 2 illustrates the sample size needed to detect, with sufficient 
power (both 80% and 90% calculated), various increases (1.5-fold, 2.0-fold, and 2.5-fold) in 
the frequency of MCMs under various assumptions of background MCM frequencies. For 
80% power to detect a doubling in the frequency of all MCMs, a sample size of 502 is 
needed if baseline frequency of MCM is 2.8%, and 873 exposures are needed if baseline 
frequency of MCM is 1.6%. Protocol-driven sample size goals with stopping rules are 
essential to creating a balance between the collection of safety information and the 
manufacturer’s resource commitment.
CONCLUSIONS
During the 18 years of the International Lamotrigine Pregnancy Registry, much was learned 
about the strengths and weaknesses of its design. Since its inception in 1992, the science of 
conducting pregnancy exposure registries has expanded, and methodologies have generally 
become more complex. To be successful, the lifecycle of a registry requires flexibility and 
continuous re-assessment of enrollment, recruitment, and retention methods and the 
availability of comparison data.
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• Operating an international pregnancy registry involves considerable logistical 
challenges that may impact enrollment and external validity; therefore, the 
efficiency of future pregnancy registries might be maximized by concentrating 
efforts on a smaller number of countries.
• Data collection in a pregnancy registry should be limited to a core, minimal 
dataset to simplify participation and promote complete reporting. The minimal 
dataset should focus on data required for assessing the exposure-outcome 
relationship and the potential for bias.
• Loss to follow-up can be high in pregnancy registries and may not be addressed 
through monetary compensation for the reporters’ time.
• The choice of comparison data for a pregnancy registry, whether from an 
internal or external source, is complex. Descriptive comparisons of reported 
MCM frequencies across multiple sources may provide a means of assessing the 
robustness of the Registry data and placing further context around emerging 
Registry results.
• Closure of the registry should be guided by discontinuation criteria that are 
defined a priori in the registry protocol.
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Cumulative enrollment of prospective cases by reporting period and therapy type, 
International Lamotrigine Pregnancy Registry, 1999–2009. Note: Yearly reports of 
lamotrigine exposure prior to 1999 were excluded due to low enrollment numbers. From 
1992–1999, the Registry enrolled a total of 200 reports overall (monotherapy and 
polytherapy).
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Stability of major congenital malformation frequency estimates over time by first trimester 
lamotrigine monotherapy exposure sample size, International Lamotrigine Pregnancy 
Registry, 1999–2010. [1] For the purposes of the calculation of risk, an outcome is defined 
as a live infant with or without a birth defect, or an induced abortion or stillbirth with a birth 
defect. Spontaneous abortions with or without a defects are excluded. [2] Confidence 
intervals developed using methods described in Fleiss.36
Sinclair et al. Page 14

























Sinclair et al. Page 15
Table 1
Completeness of reporting of exposure and outcome variables among prospective enrollments with known 
outcomes, International Lamotrigine Pregnancy Registry, 1992–2009
Variable n (%)
Overall sample sizes
 Prospectively enrolled pregnancies 3416
 Pregnancies lost to follow-up 972 (28.5)
 Pregnancies with known outcome 2444 (71.5)
 Pregnancy outcomes*,
† 2492
  Outcomes with MCM (all exposure groups)* 87
  Outcomes exposed to monotherapy 1817 (72.9)
  Outcomes exposed to polytherapy 675 (27.1)
Completeness of exposure variable reporting
 Total prospectively enrolled pregnancies 2444
  Earliest trimester of exposure 2440 (99.8)
  Exposure dose in earliest trimester of exposure 2357 (96.4)
  Date of LMP or estimated date of delivery 2320 (94.9)
  Maternal age 2301 (94.1)
  Race 2080(85.1)
  Prenatal testing in current pregnancy 1429 (58.5)
Completeness of outcome variable reporting
 Total pregnancy outcome
† 2492
 Gestational age 2386 (95.7)
 Birth weight 1780 (71.4)
 Birth length 1205 (48.4)
 Head circumference 658 (26.4)
MCM, major congenital malformation.
LMP = first day of last menstrual period.
*
Detailed final results available elsewhere.12,13
†
Includes 43 sets of twins, one set of triplets, and one set of quadruplets.
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Table 2
Sample size needed to detect increases in major congenital malformations frequency from given baseline with 
given power for a prospective cohort study.*












80 1.6 2720 873 479
2.0 2175 698 383
2.8 1539 502 275
90 1.6 3545 1124 616
2.0 2835 898 492
2.8 2012 645 337
MCM, major congenital malformation.
*
Numeric results for testing H0: P = P0 versus H1: P>P0 using a one-sided Z test with S(P hat) to estimate the standard deviation with a 
continuity. Calculations were based on a target alpha of 0.025, though actual calculated alpha <0.025.
†
Baseline MCM frequencies based on general population data. Ranges from 2.1–2.8% depending on whether MCM frequency was determined at 
birth or up to six years of age14,15 and 1.6%–2.2% within first five days of life depending on whether chromosomal and genetic anomalies were 
included.16
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